COR vs CVS

For growth investors, Cencora, Inc.

(COR) is the stronger pick with 9. 3% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Cencora, Inc. (COR) offers the better valuation at 32. 8x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Cencora, Inc. (COR) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cencora, Inc.

(COR) is the cheapest at 32. 8x versus CVS Health Corporation at 65. 1x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Cencora, Inc.

(COR) delivered a total return of +120. 0%, compared to +19. 8% for CVS Health Corporation (CVS). Over 10 years, the gap is even starker: COR returned +276. 7% versus CVS's +6. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cencora, Inc.

(COR) is the lower-risk stock at 0. 00β versus CVS Health Corporation's 0. 13β — meaning CVS is approximately 4220% more volatile than COR relative to the S&P 500. On balance sheet safety, CVS Health Corporation (CVS) carries a lower debt/equity ratio of 124% versus 6% for Cencora, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cencora, Inc.

(COR) is pulling ahead at 9. 3% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Cencora, Inc. grew EPS 5. 7% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, COR leads at 10. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cencora, Inc.

(COR) is the more profitable company, earning 0. 5% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CVS leads at 2. 6% versus 1. 1% for COR. At the gross margin level — before operating expenses — CVS leads at 13. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

4x forward P/E versus 14. 7x for Cencora, Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COR: 54. 5% to $403. 29.

All stocks in this comparison pay dividends.

CVS Health Corporation (CVS) offers the highest yield at 3. 0%, versus 0. 9% for Cencora, Inc. (COR).

For long-horizon retirement investors, Cencora, Inc.

(COR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00), 0. 9% yield, +276. 7% 10Y return). Both have compounded well over 10 years (COR: +276. 7%, CVS: +6. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.